Interview with Dr. David Yang, President, MicroConstants China
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Address: Suite 1-201, Building 18
99 Kechuang 14th Street
BDA, Beijing 101111
P.R.China
Tel: +86 (10) 59776728
Web: http://www.microconstants.com.cn/
MicroConstants China is a Contract Research Organization (CRO) that provides premier quality bioanalytical services, integrated clinical trial management services，IND-enabling drug metabolism (DMPK) assays, pharmacokinetic analysis, ELISA immunoassay, biomarker analysis, and quality system consulting to pharmaceutical/biotech companies and research institutes worldwide. Our in-house OECD GLP compliant bioanalytical laboratory specializes in method development, method validation, and sample analysis of small molecules, proteins, and peptides using LC/MS/MS, HPLC/UV, and ELISA for preclinical and clinical PK samples.
Our mission is to provide GLP/GCP compliant preclinical and clinical contract service in China to meet global product registration requirement.
Our goal is to conduct contract research service according to global recognized quality standards to ensure data integrity, accuracy, traceability and safety. Through vigorous audit of data, qualification and training of our partnering clinical site, open communication and quick resolve of our clients’ concern, we expedite our clients drug development process by providing data that meet various regulatory agencies requirement.
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech,…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC…
Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s…
China is rapidly maturing into a global hub for innovation, offering speed, scale, and cost advantages in clinical trials that few markets can match. Andy Liu, Managing Director China for…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lilly’s US$345M AI-driven BsAb licensing deal with XtalPi, IVACTA’s RMB 100M fundraising for in vivo CAR-T therapies, Vigonvita’s HKD…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Innovent’s record-breaking US$11.4 billion BsAb and ADC partnership with Takeda, DualityBio’s plans for a STAR Market IPO after positive…
See our Cookie Privacy Policy Here
